Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation

Philippe Beauchemin, Raffaele Iorio, Anthony L. Traboulsee, Thalia Field, Anna V. Tinker, Robert L. Carruthers

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background Paraneoplastic syndromes are remote effects of cancer caused by an autoimmune response triggered by tumor cells. Paraneoplastic Neuromyelitis Optica Spectrum Disorders (NMOSD) has been previously described, but the underlying mechanism for these rare cases is not well characterized. This paper presents a newly described case series of paraneoplastic NMOSD, including 2 new histological types of cancer and histological validation. Methods The UBC NMO clinic database was surveyed and identified 6 patients with paraneoplastic NMOSD. In 2 cases, aquaporin-4 (AQP4) immunoreactivity was assessed on patients’ tumor specimens. Results The mean age at NMOSD diagnosis was 56 years old and 5/6 patients were older than 50 years old. 4/6 patients with paraneoplastic NMOSD have positive AQP4 antibodies. The median time between NMOSD and cancer was 12 months. Two new cancer types- serous ovarian carcinoma and adrenocortical carcinoma - were found in paraneoplastic NMOSD cases. A serous ovarian carcinoma and a thymoma, found in patients with AQP4 serological evidence, showed a positive reactivity to AQP4 immunostaining. Conclusions Our findings will increase the recognition of NMOSD as a paraneoplastic syndrome. Cancer cells can express AQP4, increasing the likelihood of a direct mechanism between cancer cells and the development of NMOSD in paraneoplastic cases.

Original languageEnglish
Pages (from-to)37-42
Number of pages6
JournalMultiple Sclerosis and Related Disorders
Volume20
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Neuromyelitis Optica
Aquaporin 4
Neoplasms
Paraneoplastic Syndromes
Adrenocortical Carcinoma
Carcinoma
Thymoma
Autoimmunity
Ovarian Neoplasms
Databases

Keywords

  • Immunology
  • Neuromyelitis optica
  • Paraneoplastic Syndrome

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Paraneoplastic Neuromyelitis Optica Spectrum Disorder : A single center cohort description with two cases of histological validation. / Beauchemin, Philippe; Iorio, Raffaele; Traboulsee, Anthony L.; Field, Thalia; Tinker, Anna V.; Carruthers, Robert L.

In: Multiple Sclerosis and Related Disorders, Vol. 20, 01.02.2018, p. 37-42.

Research output: Contribution to journalArticle

Beauchemin, Philippe ; Iorio, Raffaele ; Traboulsee, Anthony L. ; Field, Thalia ; Tinker, Anna V. ; Carruthers, Robert L. / Paraneoplastic Neuromyelitis Optica Spectrum Disorder : A single center cohort description with two cases of histological validation. In: Multiple Sclerosis and Related Disorders. 2018 ; Vol. 20. pp. 37-42.
@article{306bc595cd104be78de4101a5e17fa6c,
title = "Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation",
abstract = "Background Paraneoplastic syndromes are remote effects of cancer caused by an autoimmune response triggered by tumor cells. Paraneoplastic Neuromyelitis Optica Spectrum Disorders (NMOSD) has been previously described, but the underlying mechanism for these rare cases is not well characterized. This paper presents a newly described case series of paraneoplastic NMOSD, including 2 new histological types of cancer and histological validation. Methods The UBC NMO clinic database was surveyed and identified 6 patients with paraneoplastic NMOSD. In 2 cases, aquaporin-4 (AQP4) immunoreactivity was assessed on patients’ tumor specimens. Results The mean age at NMOSD diagnosis was 56 years old and 5/6 patients were older than 50 years old. 4/6 patients with paraneoplastic NMOSD have positive AQP4 antibodies. The median time between NMOSD and cancer was 12 months. Two new cancer types- serous ovarian carcinoma and adrenocortical carcinoma - were found in paraneoplastic NMOSD cases. A serous ovarian carcinoma and a thymoma, found in patients with AQP4 serological evidence, showed a positive reactivity to AQP4 immunostaining. Conclusions Our findings will increase the recognition of NMOSD as a paraneoplastic syndrome. Cancer cells can express AQP4, increasing the likelihood of a direct mechanism between cancer cells and the development of NMOSD in paraneoplastic cases.",
keywords = "Immunology, Neuromyelitis optica, Paraneoplastic Syndrome",
author = "Philippe Beauchemin and Raffaele Iorio and Traboulsee, {Anthony L.} and Thalia Field and Tinker, {Anna V.} and Carruthers, {Robert L.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.msard.2017.12.012",
language = "English",
volume = "20",
pages = "37--42",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

TY - JOUR

T1 - Paraneoplastic Neuromyelitis Optica Spectrum Disorder

T2 - A single center cohort description with two cases of histological validation

AU - Beauchemin, Philippe

AU - Iorio, Raffaele

AU - Traboulsee, Anthony L.

AU - Field, Thalia

AU - Tinker, Anna V.

AU - Carruthers, Robert L.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Background Paraneoplastic syndromes are remote effects of cancer caused by an autoimmune response triggered by tumor cells. Paraneoplastic Neuromyelitis Optica Spectrum Disorders (NMOSD) has been previously described, but the underlying mechanism for these rare cases is not well characterized. This paper presents a newly described case series of paraneoplastic NMOSD, including 2 new histological types of cancer and histological validation. Methods The UBC NMO clinic database was surveyed and identified 6 patients with paraneoplastic NMOSD. In 2 cases, aquaporin-4 (AQP4) immunoreactivity was assessed on patients’ tumor specimens. Results The mean age at NMOSD diagnosis was 56 years old and 5/6 patients were older than 50 years old. 4/6 patients with paraneoplastic NMOSD have positive AQP4 antibodies. The median time between NMOSD and cancer was 12 months. Two new cancer types- serous ovarian carcinoma and adrenocortical carcinoma - were found in paraneoplastic NMOSD cases. A serous ovarian carcinoma and a thymoma, found in patients with AQP4 serological evidence, showed a positive reactivity to AQP4 immunostaining. Conclusions Our findings will increase the recognition of NMOSD as a paraneoplastic syndrome. Cancer cells can express AQP4, increasing the likelihood of a direct mechanism between cancer cells and the development of NMOSD in paraneoplastic cases.

AB - Background Paraneoplastic syndromes are remote effects of cancer caused by an autoimmune response triggered by tumor cells. Paraneoplastic Neuromyelitis Optica Spectrum Disorders (NMOSD) has been previously described, but the underlying mechanism for these rare cases is not well characterized. This paper presents a newly described case series of paraneoplastic NMOSD, including 2 new histological types of cancer and histological validation. Methods The UBC NMO clinic database was surveyed and identified 6 patients with paraneoplastic NMOSD. In 2 cases, aquaporin-4 (AQP4) immunoreactivity was assessed on patients’ tumor specimens. Results The mean age at NMOSD diagnosis was 56 years old and 5/6 patients were older than 50 years old. 4/6 patients with paraneoplastic NMOSD have positive AQP4 antibodies. The median time between NMOSD and cancer was 12 months. Two new cancer types- serous ovarian carcinoma and adrenocortical carcinoma - were found in paraneoplastic NMOSD cases. A serous ovarian carcinoma and a thymoma, found in patients with AQP4 serological evidence, showed a positive reactivity to AQP4 immunostaining. Conclusions Our findings will increase the recognition of NMOSD as a paraneoplastic syndrome. Cancer cells can express AQP4, increasing the likelihood of a direct mechanism between cancer cells and the development of NMOSD in paraneoplastic cases.

KW - Immunology

KW - Neuromyelitis optica

KW - Paraneoplastic Syndrome

UR - http://www.scopus.com/inward/record.url?scp=85039756288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039756288&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2017.12.012

DO - 10.1016/j.msard.2017.12.012

M3 - Article

C2 - 29291482

AN - SCOPUS:85039756288

VL - 20

SP - 37

EP - 42

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -